Anemia And Other Blood Disorder Drugs Global Market Report 2024

Description

“Anemia And Other Blood Disorder Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anemia and other blood disorder drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anemia and other blood disorder drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The anemia and other blood disorder drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Iron Deficiency Anemia; Chronic Kidney Disease Anemia; Sickle Cell Anemia; Aplastic Anemia
2) By Route of Administration: Oral; Injectable
3) By Distribution Channel: Hospitals Pharmacy; Online Pharmacy; Pharmacy
Sub-Segments- By Anemia Type: Microcytic (Low MCV), Normocytic (Normal MCV), Macrocytic (High MCV)
Companies Mentioned: Amgen Inc; GlaxoSmithKline plc; Akebia Therapeutics Inc.; Bayer AG; Pfizer Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Anemia and Other Blood Disorder Drugs encompass pharmaceuticals used for the treatment of anemia and related blood disorders. These conditions typically arise when medications trigger the body's immune system to erroneously attack its own red blood cells, leading to hemolysis, a process in which red blood cells prematurely break down.

The primary categories of drugs for anemia and other blood disorders include those for iron deficiency anemia, chronic kidney disease-related anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia, a prevalent form of anemia, occurs when the blood lacks a sufficient number of healthy red blood cells responsible for transporting oxygen to the body's cells. Anemia can be further classified into microcytic (low MCV), normocytic (normal MCV), and macrocytic (high MCV) types. These drugs are administered through various methods, including oral and injectable, and are distributed through channels such as hospital pharmacies, online pharmacies, and traditional retail pharmacies.

The anemia and other blood disorder drugs market research report are one of a series of new reports from The Business Research Company that provides anemia and other blood disorder drugs market statistics, including anemia and other blood disorder drugs industry global market size, regional shares, competitors with anemia and other blood disorder drugs market share, detailed anemia and other blood disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anemia and other blood disorder drugs industry. This anemia and other blood disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anemia and other blood disorder drugs market size has grown strongly in recent years. It will grow from $11.13 billion in 2023 to $11.91 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth observed during the historical period can be attributed to factors such as the prevalence of these diseases, global health initiatives, an aging population, pharmaceutical innovations, and increased patient awareness.

The anemia and other blood disorder drugs market size is expected to see strong growth in the next few years. It will grow to $15.49 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth in the forecast period can be attributed to emerging markets, global demographic trends, and various economic factors. Key trends to watch for in this period include increased investments in research and development, ongoing technological advancements, the emergence of biologics and targeted therapies, the development of gene therapies, the expansion of telemedicine and remote monitoring, the granting of orphan drug designations, and an increase in mergers and acquisitions within the industry.

The rising prevalence of anemia worldwide is a significant driver for the market. Unhealthy lifestyles, shifting dietary patterns, and heightened stress levels have led to an increase in anemia cases across the globe. As an example, anemia has become a common health issue in the elderly population, with a prevalence rate of approximately 17% among those aged over 65. The World Bank has reported that anemia ranks as the 8th most prevalent disease among women and young individuals. This increase in anemia prevalence contributes to the growth of the market for anemia and other blood disorder drugs.

The increasing demand for personalized medicine is expected to drive the growth of the anemia and other blood disorder drugs market. Personalized medicine involves using an individual's genetic profile to make decisions regarding disease prevention, diagnosis, and treatment. This approach offers more effective and precisely targeted therapies for anemia and other blood disorders, leading to better and longer-lasting patient health outcomes, making medical treatment more efficient and effective. For example, in March 2023, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022, and around 12 of these therapeutic NMEs are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the increasing demand for personalized medicine is fueling the growth of the anemia and other blood disorder drugs market.

The growing utilization of biologics for the treatment of anemia and other blood disorders has become a prominent trend. Biologics are substances made from proteins, sugars, nucleic acids, or a combination of these components, often derived from living organisms like humans, animals, or microorganisms, and may contain living organism components. This increasing preference for biologics over traditional drugs has led to a reduced number of drugs used in treating anemia and other blood disorders, impacting the market. For instance, Hospira, a medical device and pharmaceutical company, submitted its initial biologics license application to the FDA for a drug designed to treat anemia. Furthermore, the FDA approved the first Epoetin Alfa biosimilar for anemia treatment associated with chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV infection. The growing adoption of biologics is expected to hinder the growth of the anemia and other blood disorder drugs market.

Companies operating in the anemia and other blood disorder drugs market are increasingly engaging in collaborative efforts with government agencies to jointly develop and commercialize specific drugs. These collaborations involve the sharing of knowledge, technology, and costs, providing a platform for addressing challenges such as expiring licenses and navigating a stringent regulatory environment. For instance, in March 2023, Disc Medicine initiated a collaboration with the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) for Phase 1/2 and Phase 2 clinical trials of biopterin in adult patients with Diamond-Blackfan Anemia (DBA) and iron deficiency anemia. These studies will be conducted and funded by the NIH through a cooperative research and development agreement (CRADA).

Leading companies in the anemia and other blood disorder drugs market are intensifying their efforts to introduce innovative medications, gaining a competitive advantage in the industry. These novel medications represent significant advancements or new approaches to treating medical conditions and diseases. For example, in August 2023, Bristol-Myers Squibb Company, a prominent US-based pharmaceutical firm, secured approval from the United States Food and Drug Administration (FDA) for Reblozyl as the first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes. Reblozyl stands out as the first therapy to demonstrate its superiority compared to erythropoiesis-stimulating agents (ESAs) in treating MDS-related anemia, as evidenced by interim results from the pivotal Phase 3 COMMANDS study. The approval was based on data from the COMMANDS study, a global Phase 3 trial showing that nearly twice as many Reblozyl-treated patients achieved transfusion independence of at least 12 weeks, along with a concurrent hemoglobin increase when compared to Epoetin alfa.

In October 2022, Pfizer, a renowned pharmaceutical company based in the United States, acquired Global Blood Therapeutics Inc. for an undisclosed sum. This strategic acquisition enabled Pfizer to enhance its drug development portfolio and offer several promising best-in-class treatments to individuals suffering from sickle cell disease. Global Blood Therapeutics Inc. is a US-based biotechnology company specializing in the field of anemia and other blood disorder drugs.

Major companies operating in the anemia and other blood disorder drugs market include Amgen Inc., GlaxoSmithKline PLC, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., GlycoMimetics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Pieris Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., Allergan U.S. Inc., Meda Consumer Healthcare Inc., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Galenica Ltd., Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., uniQure N.V., Rubius Therapeutics Inc., BioMarin Pharmaceutical Inc., Grifols S.A., Orchard Therapeutics plc

North America was the largest region in the anemia and other blood disorder drugs market in 2023. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anemia and other blood disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The anemia and other blood disorder drugs market consists of sales of folate analogues, multivitamin and mineral supplements, iron supplements, and erythropoiesis-stimulating agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r9039

1. Executive Summary

2. Anemia And Other Blood Disorder Drugs Market Characteristics

3. Anemia And Other Blood Disorder Drugs Market Trends And Strategies

4. Anemia And Other Blood Disorder Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Anemia And Other Blood Disorder Drugs Market Size and Growth

5.1. Global Anemia And Other Blood Disorder Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Anemia And Other Blood Disorder Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Anemia And Other Blood Disorder Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Anemia And Other Blood Disorder Drugs Market Segmentation

6.1. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Iron Deficiency Anemia
Chronic Kidney Disease Anemia
Sickle Cell Anemia
6.2. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Injectable
6.3. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Anemia Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Microcytic (Low MCV)
Normocytic (Normal MCV)
Macrocytic (High MCV)
6.4. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Online Pharmacy
Pharmacy

7. Anemia And Other Blood Disorder Drugs Market Regional And Country Analysis

7.1. Global Anemia And Other Blood Disorder Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Anemia And Other Blood Disorder Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Anemia And Other Blood Disorder Drugs Market

8.1. Asia-Pacific Anemia And Other Blood Disorder Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Anemia And Other Blood Disorder Drugs Market

9.1. China Anemia And Other Blood Disorder Drugs Market Overview
9.2. China Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Anemia And Other Blood Disorder Drugs Market

10.1. India Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Anemia And Other Blood Disorder Drugs Market

11.1. Japan Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.2. Japan Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Anemia And Other Blood Disorder Drugs Market

12.1. Australia Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Anemia And Other Blood Disorder Drugs Market

13.1. Indonesia Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Anemia And Other Blood Disorder Drugs Market

14.1. South Korea Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.2. South Korea Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Anemia And Other Blood Disorder Drugs Market

15.1. Western Europe Anemia And Other Blood Disorder Drugs Market Overview
15.2. Western Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Anemia And Other Blood Disorder Drugs Market

16.1. UK Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Anemia And Other Blood Disorder Drugs Market

17.1. Germany Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Anemia And Other Blood Disorder Drugs Market

18.5. France Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Anemia And Other Blood Disorder Drugs Market

19.9. Italy Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Anemia And Other Blood Disorder Drugs Market

20.13. Spain Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Anemia And Other Blood Disorder Drugs Market

21.1. Eastern Europe Anemia And Other Blood Disorder Drugs Market Overview
21.2. Eastern Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Anemia And Other Blood Disorder Drugs Market

22.1. Russia Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Anemia And Other Blood Disorder Drugs Market

23.1. North America Anemia And Other Blood Disorder Drugs Market Overview
23.2. North America Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Anemia And Other Blood Disorder Drugs Market

24.1. USA Anemia And Other Blood Disorder Drugs Market Overview
24.2. USA Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Anemia And Other Blood Disorder Drugs Market

25.1. Canada Anemia And Other Blood Disorder Drugs Market Overview
25.2. Canada Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Anemia And Other Blood Disorder Drugs Market

26.1. South America Anemia And Other Blood Disorder Drugs Market Overview
26.2. South America Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Anemia And Other Blood Disorder Drugs Market

27.1. Brazil Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Anemia And Other Blood Disorder Drugs Market

28.1. Middle East Anemia And Other Blood Disorder Drugs Market Overview
28.2. Middle East Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Anemia And Other Blood Disorder Drugs Market

29.1. Africa Anemia And Other Blood Disorder Drugs Market Overview
29.2. Africa Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Anemia And Other Blood Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Anemia And Other Blood Disorder Drugs Market Competitive Landscape And Company Profiles

30.1. Anemia And Other Blood Disorder Drugs Market Competitive Landscape
30.2. Anemia And Other Blood Disorder Drugs Market Company Profiles
- 30.2.1. Amgen Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. GlaxoSmithKline plc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Akebia Therapeutics Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Bayer AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Pfizer Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Anemia And Other Blood Disorder Drugs Market Competitive Benchmarking

32. Global Anemia And Other Blood Disorder Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Anemia And Other Blood Disorder Drugs Market

34. Anemia And Other Blood Disorder Drugs Market Future Outlook and Potential Analysis

34.1 Anemia And Other Blood Disorder Drugs Market In 2028 - Countries Offering Most New Opportunities
34.2 Anemia And Other Blood Disorder Drugs Market In 2028 - Segments Offering Most New Opportunities
34.3 Anemia And Other Blood Disorder Drugs Market In 2028 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer